These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20739389)

  • 1. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus.
    Leahy JL; Hirsch IB; Peterson KA; Schneider D
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4206-16. PubMed ID: 20739389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of beta-cell function by targeting beta-cell mass.
    de Koning EJ; Bonner-Weir S; Rabelink TJ
    Trends Pharmacol Sci; 2008 Apr; 29(4):218-27. PubMed ID: 18359095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity and type 2 diabetes: what can be unified and what needs to be individualized?
    Eckel RH; Kahn SE; Ferrannini E; Goldfine AB; Nathan DM; Schwartz MW; Smith RJ; Smith SR; ; ;
    Diabetes Care; 2011 Jun; 34(6):1424-30. PubMed ID: 21602431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know.
    Smith RJ; Nathan DM; Arslanian SA; Groop L; Rizza RA; Rotter JI
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1566-74. PubMed ID: 20194712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term intensified insulin treatment in type 2 diabetes: long-term effects on β-cell function.
    Retnakaran R; Zinman B
    Diabetes Obes Metab; 2012 Oct; 14 Suppl 3():161-6. PubMed ID: 22928577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
    Seaquist ER; Anderson J; Childs B; Cryer P; Dagogo-Jack S; Fish L; Heller SR; Rodriguez H; Rosenzweig J; Vigersky R; ;
    J Clin Endocrinol Metab; 2013 May; 98(5):1845-59. PubMed ID: 23589524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R; Del Prato S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of reversibility of β-cell dysfunction in response to short-term intensive insulin therapy in patients with early type 2 diabetes.
    Kramer CK; Choi H; Zinman B; Retnakaran R
    Am J Physiol Endocrinol Metab; 2013 Dec; 305(11):E1398-407. PubMed ID: 24129396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes.
    Xu W; Weng J
    J Diabetes; 2013 Sep; 5(3):268-74. PubMed ID: 23551748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term intensive insulin therapy at diagnosis in type 2 diabetes: plan for filling the gaps.
    Weng J; Retnakaran R; Ariachery C A; Ji L; Meneghini L; Yang W; Woo JT
    Diabetes Metab Res Rev; 2015 Sep; 31(6):537-44. PubMed ID: 25196375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
    Massi-Benedetti M; Orsini-Federici M
    Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of GPR119 agonists for type 2 diabetes.
    Ohishi T; Yoshida S
    Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure.
    Deng J; Wang B; Cao Y; Zhu L
    Med Hypotheses; 2011 Feb; 76(2):234-6. PubMed ID: 21071152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a combination of oral anti-diabetes drugs with basal insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes.
    Mu PW; Chen YM; Lu HY; Wen XQ; Zhang YH; Xie RY; Shu J; Wang MM; Zeng LY
    Diabetes Metab Res Rev; 2012 Mar; 28(3):236-40. PubMed ID: 21898754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.